Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc - Wikidata - wikimedia - TriplyDB

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

http://www.wikidata.org/entity/Q27655577

about

Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases Cofactor-mediated conformational control in the bifunctional kinase/RNase Ire1 X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase Active site profiling reveals coupling between domains in SRC-family kinases Crystal structure of the EphA4 protein tyrosine kinase domain in the apo- and dasatinib-bound state A genetically encoded 19F NMR probe for tyrosine phosphorylation Mechanisms of drug resistance in kinases.Molecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and Coevolution The impact of Thr91 mutation on c-Src resistance to UM-164: molecular dynamics study revealed a new opportunity for drug design.Role of Desolvation in Thermodynamics and Kinetics of Ligand Binding to a Kinase.Improved angiostatic activity of dasatinib by modulation with hydrophobic chains Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study Bruton's TK inhibitors: structural insights and evolution of clinical candidates.Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily.A framework for identification of actionable cancer genome dependencies in small cell lung cancer.Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine.Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis.Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors.Identification of Aminoimidazole and Aminothiazole Derivatives as Src Family Kinase Inhibitors.Fluorescent visualization of Src by using dasatinib-BODIPY How does a drug molecule find its target binding site?Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on it for Novel Inhibitors.Design, synthesis and cytotoxic activities of novel hybrid compounds between dihydrobenzofuran and imidazole.How and when does an anticancer drug leave its binding site?Kinase-templated abiotic reaction.Survey of solution dynamics in Src kinase reveals allosteric cross talk between the ligand binding and regulatory sites.A bioorthogonal approach for imaging the binding between Dasatinib and its target proteins inside living cells.The Yin and Yang of Tyrosine Kinase Inhibition During Experimental Polymicrobial Sepsis.Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors.Thiazoles in Peptides and Peptidomimetics Optimization of Aminoimidazole Derivatives as Src Family Kinase Inhibitors

P2860

Q27658863-C92C9756-6155-4481-B76C-47B13241537A Q27670678-C75A85D0-544C-46C8-A598-9DDEEC762895 Q27672770-656B4642-C898-4C9B-91DA-E890D2CF4630 Q27675080-E396EDF4-4755-4B93-819E-E38DED99C71D Q27675279-EA939A23-DD9C-486D-A321-53CAEAC8A5DC Q27684095-F59C7267-004A-47E3-8B20-71F167B6A54A Q27692567-CF1C89B5-B0E2-4196-8387-F3383FB088CA Q28548366-C7D28541-B309-4BEA-A364-A5DBBA18A915 Q30401596-9BCAB408-A302-4C75-9522-2BA588BAAE0A Q34680443-D588E192-D2B2-4733-AFB5-17F07504F523 Q35178869-7595F6C3-36E9-4679-A7B7-61CEED52B06D Q35181207-3451C302-5E4C-427E-AE84-F166A505E9C1 Q35181271-CAAEB06D-2535-43C0-B5F1-E98A6538C184 Q35552376-1227D499-AA2B-46F7-8748-C3782C905313 Q35752926-C3B16EB1-A7F3-4EE8-A37B-0EB56A6B94D2 Q36280842-41F1CC11-98A4-44B5-A6EB-7D4DE445E4F2 Q36342432-6D1ADD3C-294D-404E-8DE9-5C03DFB2CB7E Q36405755-19F3A643-F16D-423C-9826-671C41F3B0D8 Q37859008-F79482D1-85C5-487A-878C-E4ADD7B6B120 Q38729630-9813ED40-8A28-4E1D-AC12-DAD08A720E4F Q38823850-E2FDB3DF-6013-4D4D-8BAC-A8E1DE8A84A1 Q38994926-198B76DB-D2C5-475A-9C55-69EA930A9BFF Q39280041-44DE3EB1-2C0D-40FF-8AB8-9E91F75E94E1 Q39551009-3DB2501D-68F1-4026-A128-C2540B68B0E6 Q39556006-9658C900-088C-47A6-B8E9-89748BE5F27F Q41965081-B92D80D7-9F10-46BC-8A8B-A9F35955ADEB Q42160458-52E231BB-26AC-4A5C-A238-77DA12EFD643 Q47279026-703770D9-B08B-4C27-A34C-137874593EEF Q51423275-B6B7C563-F639-4211-8AEF-AE6ED741D0EB Q54109924-C33687A5-AC3E-414D-9C65-125110D47C16 Q54577546-C836B280-2426-489A-ACD2-F3D16AC2ADA8 Q54580789-ECDEB3CD-EBFE-4660-967F-C047C9A6F319 Q56474264-04539C14-D500-4808-9C7B-85A8F10031AE Q58696684-35E0FE26-B66F-4CC5-8868-1015629002A9

P2860

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

http://www.wikidata.org/entity/Q27655577

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

@ast

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

@en

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

@nl

type

label

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

@ast

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

@en

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

@nl

prefLabel

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

@ast

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

@en

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

@nl

P1433

Q27655577-1F0197BE-BC23-40A6-A6BB-E435A16E9037

P1476

Q27655577-CD07495F-4645-40B9-A9A7-7889DEF1FFB9

P2093

Q27655577-22F199F0-BC28-4A8F-87D4-5AE3418DEF95

Q27655577-539F3AA7-6EE4-4214-B055-51F7EAAE013E

Q27655577-5851E4B3-B979-4EBF-AD68-6AE64271EDA8

Q27655577-7841A071-0F77-449D-B1E0-10E3D0931FAD

Q27655577-C96E9DCB-45A3-470A-8ED2-48E844BD3F8E

Q27655577-E1BCCFE6-1C02-4083-AEA2-18F52D50004A

Q27655577-F2BD512A-CD08-4035-9CFB-624B22CE32BB

Q27655577-FD5E17AD-6EF6-4BCC-BB96-63AA00AEC284

P304

Q27655577-9E835778-B44B-4836-9988-30B47E2151A4

P31

Q27655577-3C72EAF4-38E3-4CB9-8E7B-D49D150E699C

P356

Q27655577-025BC741-261E-4FC5-887A-E6CFBC10E921

P407

Q27655577-8044EEF6-68A8-46CC-B80C-B475D7B1020C

P433

Q27655577-C18B1DEB-88D4-4238-8BE1-F88751C0AAE8

P478

Q27655577-56C18B2C-E025-4F85-BB8B-5FBB2004439C

P577

Q27655577-57E81182-5606-4FFA-A495-634A52AF49A8

P5875

Q27655577-986E6C41-B579-450F-AFA7-E7579710D4E5

P698

Q27655577-965BF46C-3327-49E3-9278-9BB4229055F1

P356

P1433

Journal of Medicinal Chemistry

P1476

Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc

@en

P2093

Armin Robubi

http://www.w3.org/2001/XMLSchema#string

Christian Grütter

http://www.w3.org/2001/XMLSchema#string

Daniel Rauh

http://www.w3.org/2001/XMLSchema#string

Haridas B Rode

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Simard

http://www.w3.org/2001/XMLSchema#string

Matthias Rabiller

http://www.w3.org/2001/XMLSchema#string

Matthäus Getlik

http://www.w3.org/2001/XMLSchema#string

Sabine Klüter

http://www.w3.org/2001/XMLSchema#string

P304

3915-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM9002928

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26234645

http://www.w3.org/2001/XMLSchema#string

P698

19462975

http://www.w3.org/2001/XMLSchema#string